Hydroxychloroquine is a medication used to treat rheumatoid arthritis, systemic lupus erythematosus, and other autoimmune disorders. Previous studies have shown that hydroxychloroquine and the structurally related drug chloroquine have the potential to interfere with some common urine chemistry tests, especially at high concentrations. In the related research article, we observed suspected interference with urine drug of abuse testing in a patient who ingested approximately 12 g of hydroxychloroquine in an acute overdose, with urine hydroxychloroquine concentrations exceeding 500 mg/L. This case prompted a more detailed investigation of the effects of hydroxychloroquine spiked into pooled deidentified urine specimens from a hospital clinical laboratory.
Interference After Hydroxychloroquine Intoxication: A Case Report" [1] . © 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).
Data
We investigated the effect on urine assays of hydroxychloroquine at concentration up to 1000 mg/L spiked into pools of de-identified urine specimens from the university medical center central clinical laboratory. This followed from observation that a patient with a large overdose of hydroxychloroquine showed suspected interference for some urine laboratory tests obtained for clinical care [1] . There is limited published data that hydroxychloroquine can interfere with urine protein dipstick methods [2, 3] and with some urine drug screening tests [4] . A detailed review of package inserts for drug of abuse and therapeutic drug monitoring assays did not find hydroxychloroquine reported as an interferent in any of the assays [5, 6] . Specifications Table   Subject Medicine and Dentistry Specific subject area Pathology and Medical Technology Type of data 
Value of the Data
The data provided is of value as there is currently only limited published data demonstrating interfering effects of hydroxychloroquine on urine laboratory assays. Other researchers or personnel in clinical laboratories might find this data useful as a reference for comparison. Our data set would serve as a starting point for researchers interested in future investigations studying the effects of hydroxychloroquine on urine chemistry assays marketed by vendors.
The data is of value as previous studies have not examined a wide range of urine laboratory assays commonly performed in clinical laboratories. The data provide information for 24 urine assays tested up to 1000 mg/L hydroxychloroquine, a concentration achievable in large overdose.
The 24 specific urine assays analyzed are as follows: amphetamines drug screen, amylase, benzodiazepines drug screen, buprenorphine drug screen, calcium, chloride, cocaine metabolite screen, cotinine screen, creatinine, glucose, human chorionic gonadotropin (hCG), magnesium, microalbumin, myoglobin, NGAL, opiates drug screen, oxycodone drug screen, pH, phosphorus, potassium, protein, sodium, tetrahydrocannabinol (THC) drugs screen, and urea nitrogen. Technical details on these 24 urine assays are available elsewhere [1] . The assays were initially screened in triplicate for a single deidentified pooled urine sample. Thirteen of the assays showed no absorbance or other alarms/errors and also did not have any results that differed by more than 15% from the control without hydroxychloroquine. The raw data for these 13 assays is in Table 1 . Raw data for the remaining 11 assays is in Table 2 . These were all tested in triplicate for a total of 4 separate pooled urine samples. Fig. 1 shows data for 4 of the assays (amphetamine screen, benzodiazepine screen, buprenorphine screen, and cocaine screen). An absorbance alarm was evident for all 4 samples containing 1000 mg/L hydroxychloroquine for the buprenorphine screen (Fig. 1B ). Fig. 2 shows data for another 4 of the assays (cotinine screen, microalbumin, myoglobin, and opiates screen). Positive bias and absorbance errors were evident for the cotinine assay for all 4 specimens ( Fig. 2A) . Biphasic effects of hydroxychloroquine were evident for the microalbumin assay, especially for samples 1, 2, and 4 ( Fig. 2B) . A negative bias was evident for the myoglobin assay for sample 2 (Fig. 2C ). The remaining urine samples had <21 ng/mL myoglobin and did not show any evident effect of hydroxychloroquine, although a negative bias would not be detectable in these 3 samples with the myoglobin concentrations below the lower limit of quantitation. Fig. 3 shows data for the remaining 3 assays analyzed in detail. Absorbance errors were evident for the oxycodone for all 4 samples spiked with 1000 mg/L (Fig. 3A) . A positive bias from hydroxychloroquine was evident for all 4 samples analyzed for tetrahydrocannabinol (THC; Fig. 3B ), although all 4 of these samples would still be negative in this qualitative assay.
Experimental design, materials, and methods
All analyses were performed on Roche Diagnostics cobas 8000 analyzers (c501, c502, c602, and c701). The complete list of assays with vendor name, methodology, and assay version are summarized elsewhere [1] . All assays were run in accordance with package insert instructions. A total of 4 pooled urine specimens were prepared using de-identified specimens from the clinical laboratory. All 24 assays were tested in triplicate for 1 of the urine pools. As described above, 11 of the assays were then tested and triplicate for the remaining 3 urine pools. The raw data consists of concentration or absorbance units for the specimens. It should be noted that the urine total protein method used for the data in this report uses a biuret complex method using divalent copper in alikaline solution [7] . This is in contrast to previous studies using tetrabromophenol blue [3] and pyrogallol red-molybdate methods [2] that showed interference by hydroxychloroquine. Table 2 Raw data for 13 urine assays on four separate pooled urine samples.
Assay Units
Sample # Hydroxychloroquine concentration 0 mg/L 1 mg/L 10 mg/L 100 mg/L 500 mg/L 1000 mg/L Amphetamines Drug Screen Relative 1 À268 À286 À276 À281 À271 À250 absorbance units 2 À302 À323 À309 À314 À298 À291 (positive: >0) 3 À273 À283 À284 À279 À281 À264 4 À299 À299 À295 À298 À283 À265 Benzodiazepines Drug Screen Relative 1 À187 À178 À176 À174 À171 À164 absorbance units 2 À263 À204 À209 À201 À185 À58 (positive: >0) 3 À210 À181 À183 À176 À176 À172 4 102 108 106 105 105 107 Buprenorphine Drug Screen Relative 1 À339 À441 À441 À472 À534 Absorbance error absorbance units 2 À283 À421 À410 À429 À472 Absorbance error (positive: >0) 3 À283 À393 À398 À420 À418 Absorbance error 4 À258 À389 À395 À405 À451 Absorbance error Cocaine Drug Screen Relative 1 À548 À538 À554 À557 À565 À540 absorbance units 2 À575 À587 À570 À581 À578 À558 (positive: >0) 3 À553 À543 À546 À546 À537 À536 4
À558 À560 À568 À570 À551 À552 À178 À165 À162 À163 À155 À126 absorbance units 2 À221 À191 À186 À180 À167 À152 (positive: >0) 3 À225 À206 À206 À207 À195 À201 4 À225 À210 À211 À212 À194 À180 
